Molecular Targeting Technologies (MTTI) is highlighting clinical findings on its next-generation peptide receptor radionuclide therapy agent, lutetium-177 (Lu-177)-DOTA-EB-TATE (EBTATE), at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting.
The phase 1 dose-escalation and dosimetry study, conducted in 81 patients with gastroenteropancreatic neuroendocrine tumors, found that EBTATE achieved approximately eight-fold higher tumor uptake in patients compared with conventional (Lu-177)-DOTATATE, with no kidney toxicity observed at one-year follow-up, according to the company.
The data suggest meaningful clinical responses may be achievable after only two treatment cycles, using approximately 12.5% of the cumulative radioactivity required for standard peptide receptor radionuclide therapy (PRRT), MTTI said.
